Gerresheimer AGGRRMF 66 Days Payable is 65.15 as of Aug. 2025, which is 15% below its 10-year median of 76.45. GuruFocus rates GRRMF with a GF Score™ of 66/100 and a GF Value™ of $121.69 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Gerresheimer AG ranks better than 52.45% on this metric.
The historical rank and industry rank for Gerresheimer AG's Days Payable or its related term are showing as below:
GRRMF'
s Days Payable Range Over the Past 10 Years
Min: 57.5 Med: 76.45 Max: 92.1
Current: 71.87
During the past 13 years, Gerresheimer AG's highest Days Payable was 92.10. The lowest was 57.50. And the median was 76.45.
GRRMF's Days Payable is ranked better than 52.45% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs GRRMF: 71.87
Gerresheimer AG's Days Payable
declined
from Aug. 2024 (77.36) to Aug. 2025 (65.15).
It may suggest that Gerresheimer AGaccelerated paying its suppliers.
Gerresheimer AG Days Payable Related Terms
Gerresheimer AG Days Payable Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gerresheimer AG's Days Payable for the fiscal year that ended in Nov. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gerresheimer AG (GRRMF) has a Days Payable of 65.15 as of Aug. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gerresheimer AG and its competitors. This is 15% below median its historical median of 76.45. Over the past decade, Gerresheimer AG's Days Payable has ranged from 57.50 to 92.10. According to the industry distribution chart, Gerresheimer AG ranks #378 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 47.5%.
Is Gerresheimer AG's Days Payable too high?
Gerresheimer AG's current Days Payable of 65.15 is 15% below median its 10-year median of 76.45. Over the past 10 years, this metric has ranged from a low of 57.50 to a high of 92.10. The Medical Devices & Instruments industry median Days Payable is 68.07. Gerresheimer AG's value of 65.15 is 4.3% below this industry median. Based on the distribution chart, Gerresheimer AG ranks #378 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gerresheimer AG has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #378 out of 795 companies for Days Payable. This puts Gerresheimer AG in the upper half of its industry. The industry median Days Payable is 68.07. Gerresheimer AG's value of 65.15 is 4.3% below this benchmark. Historically, Gerresheimer AG's own Days Payable has ranged from 57.50 to 92.10 over the past decade. While the company's 10-year median is 76.45 vs. the industry median of 68.07, Gerresheimer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gerresheimer AG's current Days Payable of 65.15 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gerresheimer AG and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current Days Payable is 65.15, which is 15% below median its own 10-year median of 76.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMF) is currently considered Possible Value Trap. The stock's GF Value™ is $121.69, compared to a current price of $32.10 — trading 73.6% below its estimated fair value. The current Days Payable is 65.15, which is 15% below median its 10-year median of 76.45 and 4.3% below the Medical Devices & Instruments industry median of 68.07. Gerresheimer AG's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gerresheimer AG (GRRMF), the current Days Payable is 65.15 as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $32.10 is trading 73.6% below its estimated GF Value™ of $121.69.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMF:
Days Payable: 65.15 (15% below median its 10-year median of 76.45)
GF Value™: $121.69 vs. price of $32.10 (73.6% below fair value)
Industry Position: 4.3% below the Medical Devices & Instruments median (#378 of 795)
No single metric tells the full story. See the GRRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
66GF Score
Get the complete analysis for GRRMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMF has been successfully added to your 
